CoChat

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype

Open access
Wellaway, Christopher R., Bamborough, Paul, Bernard, Sharon G., Chung, Chun-wa, Craggs, Peter D., Cutler, Leanne, Demont, Emmanuel H., Evans, John P., Gordon, Laurie, Karamshi, Bhumika, Lewis, Antonia J., Lindon, Matthew J., Mitchell, Darren J., Rioja, Inmaculada, Soden, Peter E., Taylor, Simon, Watson, Robert J., Willis, Rob, Woolven, James M., Wyspiańska, Beata S., Kerr, William J., Prinjha, Rab K. · 2020 · Journal of Medicinal Chemistry
Cited by 49

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each containing tandem bromodomains. To date, small molecule inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biological effects. To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required. In this regard, we report the discovery of a potent probe molecule possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs. Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chemical functionality appended to the previously developed I-BET151 scaffold. Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.0c00566

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 49

Metadata

Authors
Wellaway, C. R., Bamborough, P., Bernard, S. G., Chung, C.-W., Craggs, P. D., Cutler, L., Demont, E. H., Evans, J. P., Gordon, L., Karamshi, B., Lewis, A. J., Lindon, M. J., Mitchell, D. J., Rioja, I., Soden, P. E., Taylor, S., Watson, R. J., Willis, R., Woolven, J. M., Wyspiańska, B. S., Kerr, W. J., & Prinjha, R. K.
Venue
Journal of Medicinal Chemistry
Published
2020-08-03
Volume
63
Issue
17
Pages
9020-9044
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3047589966
Cited by
49
References
4
FWCI
2.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. https://app.cochat.ai/papers/10.1021/acs.jmedchem.0c00566
The paper
Wellaway, C. R., Bamborough, P., Bernard, S. G., Chung, C.-W., Craggs, P. D., Cutler, L., Demont, E. H., Evans, J. P., Gordon, L., Karamshi, B., Lewis, A. J., Lindon, M. J., Mitchell, D. J., Rioja, I., Soden, P. E., Taylor, S., Watson, R. J., Willis, R., Woolven, J. M., . . . Prinjha, R. K. (2020). Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c00566

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.